CoChat

Anticancer Effects of Niclosamide in Human Glioblastoma

Wieland, Anja, Trageser, Daniel, Gogolok, Sabine, Reinartz, Roman, Höfer, Heike, Keller, Mihaela, Leinhaas, Anke, Schelle, Ramona, Normann, Sabine, Klaas, Lil, Waha, Andreas, Koch, Philipp, Fimmers, Rolf, Pietsch, Torsten, Yachnis, Anthony T., Pincus, David W., Steindler, Dennis A., Brüstle, Oliver, Simon, Matthias, Glas, Martin, Scheffler, Björn · 2013 · Clinical Cancer Research
Cited by 156

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Purpose: Glioblastoma is a highly malignant, invariably fatal brain tumor for which effective pharmacotherapy remains an unmet medical need. Experimental Design: Screening of a compound library of 160 synthetic and natural toxic substances identified the antihelmintic niclosamide as a previously unrecognized candidate for clinical development. Considering the cellular and interindividual heterogeneity of glioblastoma, a portfolio of short-term expanded primary human glioblastoma cells (pGBM; n = 21), common glioma lines (n = 5), and noncancer human control cells (n = 3) was applied as a discovery platform and for preclinical validation. Pharmacodynamic analysis, study of cell-cycle progression, apoptosis, cell migration, proliferation, and on the frequency of multipotent/self-renewing pGBM cells were conducted in vitro, and orthotopic xenotransplantation was used to confirm anticancer effects in vivo. Results: Niclosamide led to cytostatic, cytotoxic, and antimigratory effects, strongly reduced the frequencies of multipotent/self-renewing cells in vitro, and after exposure significantly diminished the pGBMs' malignant potential in vivo. Mechanism of action analysis revealed that niclosamide simultaneously inhibited intracellular WNT/CTNNB1-, NOTCH-, mTOR-, and NF-κB signaling cascades. Furthermore, combinatorial drug testing established that a heterozygous deletion of the NFKBIA locus in glioblastoma samples could serve as a genomic biomarker for predicting a synergistic activity of niclosamide with temozolomide, the current standard in glioblastoma therapy. Conclusions: Together, our data advocate the use of pGBMs for exploration of compound libraries to reveal unexpected leads, for example, niclosamide that might be suited for further development toward personalized clinical application. Clin Cancer Res; 19(15); 4124–36. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-2895

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 156

Metadata

Authors
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., Waha, A., Koch, P., Fimmers, R., Pietsch, T., Yachnis, A. T., Pincus, D. W., Steindler, D. A., Brüstle, O., Simon, M., Glas, M., & Scheffler, B.
Venue
Clinical Cancer Research
Published
2013-07-31
Volume
19
Issue
15
Pages
4124-4136
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2142742806
Cited by
156
References
8
FWCI
7.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anticancer Effects of Niclosamide in Human Glioblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-2895
The paper
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., Waha, A., Koch, P., Fimmers, R., Pietsch, T., Yachnis, A. T., Pincus, D. W., Steindler, D. A., Brüstle, O., Simon, M., . . . Scheffler, B. (2013). Anticancer Effects of Niclosamide in Human Glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-2895

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.